{ "labelLang" : "eng", "responseDate" : "2024-03-28 20:21", "content" : { "otype" : "JournalArticle", "mtid" : 31644451, "status" : "APPROVED", "published" : true, "comment" : "Cited By :1 \n Export Date: 18 March 2021 \n CODEN: CTMCC \n Correspondence Address: Gaurav, A.; Faculty of Pharmaceutical Sciences, Malaysia; email: anand.pharma@gmail.com \n Chemicals/CAS: adenylate cyclase, 9012-42-4; balipodect, 1238697-26-1; calcium ion, 14127-61-8; cyclic AMP dependent protein kinase; cyclic AMP responsive element binding protein, 130428-87-4, 130939-96-7; cyclic GMP, 7665-99-8; cyclic GMP dependent protein kinase, 141588-27-4; guanosine triphosphate, 86-01-1; guanylate cyclase, 9054-75-5; mardepodect, 898562-94-2; nitric oxide synthase, 125978-95-2; osoresnontrine, 1189767-28-9; papaverine, 58-74-2, 61-25-6; phosphodiesterase; roflumilast, 162401-32-3; rolipram, 61413-54-5; vinpocetine, 42971-09-5 \n Tradenames: bi 409306; bpn 14770; evp 6308; iti 214; mp 10; oms 824; pf 04447943; pf 05180999; pf 2545920; pf 999; tak 063", "unhandledTickets" : 0, "deleted" : false, "lastRefresh" : "2023-01-10T09:36:10.202+0000", "lastModified" : "2020-10-29T20:01:13.831+0000", "created" : "2020-10-29T19:59:59.528+0000", "creator" : { "otype" : "Admin", "mtid" : 10026589, "link" : "/api/admin/10026589", "label" : "Rita Tichy (SE_KK_Admin5_TR, admin)", "familyName" : "Tichy", "givenName" : "Rita", "published" : true, "oldId" : 10026589, "snippet" : true }, "lastDuplumSearch" : "2023-06-02T13:50:19.982+0000", "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Journal Article", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 1134514, "link" : "/api/subtype/1134514", "label" : "Survey paper (Journal Article)", "name" : "Összefoglaló cikk", "nameEng" : "Survey paper", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Journal Article", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 102, "published" : true, "oldId" : 1134514, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Scientific", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "English", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Al-Nema, M.Y.", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 93905911, "link" : "/api/authorship/93905911", "label" : "Al-Nema, M.Y.", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "corresponding" : false, "familyName" : "Al-Nema", "givenName" : "M.Y.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Author", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 93905912, "link" : "/api/authorship/93905912", "label" : "Gaurav, A.", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : true, "corresponding" : false, "familyName" : "Gaurav", "givenName" : "A.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Author", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true } ], "title" : "Phosphodiesterase as a target for cognition enhancement in schizophrenia", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 17845011, "link" : "/api/publicationidentifier/17845011", "label" : "DOI: 10.2174/1568026620666200613202641", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.2174/1568026620666200613202641", "realUrl" : "https://doi.org/10.2174/1568026620666200613202641", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 18541060, "link" : "/api/publicationidentifier/18541060", "label" : "WoS: 000590234400006", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "https://www.webofscience.com/wos/woscc/full-record/WOS:@@@", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000590234400006", "realUrl" : "https://www.webofscience.com/wos/woscc/full-record/WOS:000590234400006", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 17845010, "link" : "/api/publicationidentifier/17845010", "label" : "Scopus: 85092465977", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "85092465977", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85092465977", "published" : false, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 10003085, "link" : "/api/journal/10003085", "label" : "CURRENT TOPICS IN MEDICINAL CHEMISTRY 1568-0266 1873-4294", "pIssn" : "1568-0266", "eIssn" : "1873-4294", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 10003085, "snippet" : true }, "volume" : "20", "issue" : "26", "firstPage" : "2404", "lastPage" : "2421", "firstPageOrInternalIdForSort" : "2404", "pageLength" : 18, "publishedYear" : 2020, "digital" : null, "printed" : null, "sourceYear" : 2020, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2023-01-10", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 2, "citedCount" : 2, "ratings" : [ { "otype" : "SjrRating", "mtid" : 10782136, "link" : "/api/sjrrating/10782136", "label" : "sjr:Q2 (2020) Scopus - Drug Discovery CURRENT TOPICS IN MEDICINAL CHEMISTRY 1568-0266 1873-4294", "listPos" : 57, "rankValue" : 0.49, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 3002, "link" : "/api/classificationexternal/3002", "label" : "Scopus - Drug Discovery", "published" : true, "oldId" : 3002, "snippet" : true }, "ranking" : "Q2", "calculation" : "DIRECT", "published" : true, "snippet" : true } ], "ratingsForSort" : "Q2", "references" : [ { "otype" : "Reference", "mtid" : 437040, "link" : "/api/reference/437040", "label" : "1. Hindmarch, I., Fuchs, H.H., Erzigkeit, H., Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes (1991) Int. Clin. Psychopharmacol, 6 (1), pp. 31-43. , http://dx.doi.org/10.1097/00004850-199100610-00005, PMID: 2071888", "listPosition" : 1, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437039, "link" : "/api/reference/437039", "label" : "2. DeNoble, V.J., Vinpocetine enhances retrieval of a step-through passive avoidance response in rats (1987) Pharmacol. Biochem. Behav, 26 (1), pp. 183-186. , http://dx.doi.org/10.1016/0091-3057(87)90552-1, PMID: 3562490", "listPosition" : 2, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437038, "link" : "/api/reference/437038", "label" : "3. Lendvai, B., Zelles, T., Rozsa, B., Vizi, E.S., A vinca alkaloid enhances morphological dynamics of dendritic spines of neocortical layer 2/3 pyramidal cells (2003) Brain Res. Bull, 59 (4), pp. 257-260. , http://dx.doi.org/10.1016/S0361-9230(02)00873-0, PMID: 12464397", "listPosition" : 3, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437037, "link" : "/api/reference/437037", "label" : "4. Molnár, P., Gaál, L., Horváth, C., The impairment of long-term potentiation in rats with medial septal lesion and its restoration by cognition enhancers (1994) Neurobiology (Bp.), 2 (3), pp. 255-266. , PMID: 7881404", "listPosition" : 4, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437036, "link" : "/api/reference/437036", "label" : "5. Molnár, P., Gaál, L., Effect of different subtypes of cognition enhancers on long-term potentiation in the rat dentate gyrus in vivo (1992) Eur. J. Pharmacol, 215 (1), pp. 17-22. , http://dx.doi.org/10.1016/0014-2999(92)90602-Z, PMID: 1516646", "listPosition" : 5, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437035, "link" : "/api/reference/437035", "label" : "6. Nicholson, C.D., Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia (1990) Psychopharmacology (Berl.), 101 (2), pp. 147-159. , http://dx.doi.org/10.1007/BF02244119, PMID: 2190256", "listPosition" : 6, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437034, "link" : "/api/reference/437034", "label" : "7. Vereczkey, L., Pharmacokinetics and metabolism of vincamine and related compounds (1985) Eur. J. Drug Metab. Pharmacokinet, 10 (2), pp. 89-103. , http://dx.doi.org/10.1007/BF03189702, PMID: 3899662", "listPosition" : 7, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437033, "link" : "/api/reference/437033", "label" : "8. Winterer, G., Weinberger, D.R., Genes, dopamine and cortical signal-to-noise ratio in schizophrenia (2004) Trends Neurosci, 27 (11), pp. 683-690. , http://dx.doi.org/10.1016/j.tins.2004.08.002, PMID: 15474169", "listPosition" : 8, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437032, "link" : "/api/reference/437032", "label" : "9. Winterer, G., Cortical microcircuits in schizophrenia--the dopamine hypothesis revisited (2006) Pharmacopsychiatry, 39, p. S68S71. , http://dx.doi.org/10.1055/s-2006-931498, (Suppl. 1), PMID: 16508900", "listPosition" : 9, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437031, "link" : "/api/reference/437031", "label" : "10. Arnsten, A.F., The neurobiology of thought: the groundbreaking discoveries of Patricia Goldman-Rakic 1937-2003 (2013) Cereb. Cortex, 23 (10), pp. 2269-2281. , http://dx.doi.org/10.1093/cercor/bht195, PMID: 23926115", "listPosition" : 10, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437030, "link" : "/api/reference/437030", "label" : "11. Liemburg, E.J., Knegtering, H., Klein, H.C., Kortekaas, R., Aleman, A., Antipsychotic medication and prefrontal cortex activation: a review of neuroimaging findings (2012) Eur. Neuropsychopharmacol, 22 (6), pp. 387-400. , http://dx.doi.org/10.1016/j.euroneuro.2011.12.008, PMID: 22300864", "listPosition" : 11, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437029, "link" : "/api/reference/437029", "label" : "12. Lu, Y-F., Kandel, E.R., Hawkins, R.D., Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus (1999) J. Neurosci, 19 (23), pp. 10250-10261. , http://dx.doi.org/10.1523/JNEUROSCI.19-23-10250.1999, PMID: 10575022", "listPosition" : 12, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437028, "link" : "/api/reference/437028", "label" : "13. Ko, G.Y., Kelly, P.T., Nitric oxide acts as a postsynaptic signaling molecule in calcium/calmodulin-induced synaptic potentiation in hippocampal CA1 pyramidal neurons (1999) J. Neurosci, 19 (16), pp. 6784-6794. , http://dx.doi.org/10.1523/JNEUROSCI.19-16-06784.1999, PMID: 10436036", "listPosition" : 13, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437027, "link" : "/api/reference/437027", "label" : "14. Nakashima, M., Imada, H., Shiraishi, E., Ito, Y., Suzuki, N., Miyamoto, M., Taniguchi, T., Iwashita, H., Phosphodiesterase 2A inhibitor TAK-915 ameliorates cognitive impairments and social withdrawal in N-methyl-D-aspartate receptor antagonist–induced rat models of schizophrenia (2018) J. Pharmacol. Exp. Ther, 365 (1), pp. 179-188. , http://dx.doi.org/10.1124/jpet.117.245506, PMID: 29440309", "listPosition" : 14, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437026, "link" : "/api/reference/437026", "label" : "15. Rosenbrock, H., Inhibition of cGMP-metabolizing PDEs as target for cognitive enhancement (2015) BMC Pharmacol. Toxicol, 16 (S1). , http://dx.doi.org/10.1186/2050-6511-16-S1-A19", "listPosition" : 15, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437025, "link" : "/api/reference/437025", "label" : "16. Springer: Berlin", "listPosition" : 16, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437024, "link" : "/api/reference/437024", "label" : "17. O’Donnell, J.M., Eds.", "listPosition" : 17, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437023, "link" : "/api/reference/437023", "label" : "18. Xu, Y.", "listPosition" : 18, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437022, "link" : "/api/reference/437022", "label" : "19. Dorner-Ciossek, C., Kroker, K., Rosenbrock, H., Role of PDE9 in Cognition (2017) Phosphodiesterase: CNS Functions and Diseases, pp. 231-254. , http://dx.doi.org/10.1007/978-3-319-58811-7_9, Zhang, H.T.", "listPosition" : 19, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437021, "link" : "/api/reference/437021", "label" : "20. Heckman, P.R.A., van Duinen, M.A., Bollen, E.P.P., Nishi, A., Wennogle, L.P., Blokland, A., Prickaerts, J., Phosphodiesterase inhibition and regulation of dopaminergic frontal and striatal functioning: clinical implications (2016) Int. J. Neuropsychopharmacol, 19 (10), p. 30. , http://dx.doi.org/10.1093/ijnp/pyw030, PMID: 27037577", "listPosition" : 20, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437020, "link" : "/api/reference/437020", "label" : "21. Nishi, A., Snyder, G.L., Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission (2010) J. Pharmacol. Sci, 114 (1), pp. 6-16. , http://dx.doi.org/10.1254/jphs.10R01FM, PMID: 20716858", "listPosition" : 21, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437019, "link" : "/api/reference/437019", "label" : "22. Nishi, A., Kuroiwa, M., Shuto, T., Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons (2011) Front. Neuroanat, 5, p. 43. , http://dx.doi.org/10.3389/fnana.2011.00043, PMID: 21811441", "listPosition" : 22, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437018, "link" : "/api/reference/437018", "label" : "23. Menniti, F.S., Faraci, W.S., Schmidt, C.J., Phosphodiesterases in the CNS: targets for drug development (2006) Nat. Rev. Drug Discov, 5 (8), pp. 660-670. , http://dx.doi.org/10.1038/nrd2058, PMID: 16883304", "listPosition" : 23, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437017, "link" : "/api/reference/437017", "label" : "24. Lakics, V., Karran, E.H., Boess, F.G., Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues (2010) Neuropharmacology, 59 (6), pp. 367-374. , http://dx.doi.org/10.1016/j.neuropharm.2010.05.004, PMID: 20493887", "listPosition" : 24, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437016, "link" : "/api/reference/437016", "label" : "25. Tomimatsu, Y., Cash, D., Suzuki, M., Suzuki, K., Bernanos, M., Simmons, C., Williams, S.C.R., Kimura, H., TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge (2016) Neuroscience, 339, pp. 180-190. , http://dx.doi.org/10.1016/j.neuroscience.2016.10.006, PMID: 27725212", "listPosition" : 25, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437015, "link" : "/api/reference/437015", "label" : "26. Reneerkens, O.A., Rutten, K., Steinbusch, H.W., Blokland, A., Prickaerts, J., Selective phosphodiesterase inhibitors: a promising target for cognition enhancement (2009) Psychopharmacology (Berl.), 202 (1-3), pp. 419-443. , http://dx.doi.org/10.1007/s00213-008-1273-x, PMID: 18709359", "listPosition" : 26, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437014, "link" : "/api/reference/437014", "label" : "27. Tsai, L-C.L., Shimizu-Albergine, M., Beavo, J.A., The high-affinity cAMP-specific phosphodiesterase 8B controls steroidogenesis in the mouse adrenal gland (2011) Mol. Pharmacol, 79 (4), pp. 639-648. , http://dx.doi.org/10.1124/mol.110.069104, PMID: 21187369", "listPosition" : 27, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437013, "link" : "/api/reference/437013", "label" : "28. Zhang, L., Murray, F., Zahno, A., Kanter, J.R., Chou, D., Suda, R., Fenlon, M., Insel, P.A., Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia (2008) Proc. Natl. Acad. Sci. USA, 105 (49), pp. 19532-19537. , http://dx.doi.org/10.1073/pnas.0806152105, PMID: 19033455", "listPosition" : 28, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437012, "link" : "/api/reference/437012", "label" : "29. Safavi, M., Baeeri, M., Abdollahi, M., New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders (2013) Expert Opin. Drug Discov, 8 (6), pp. 733-751. , http://dx.doi.org/10.1517/17460441.2013.787986, PMID: 23570245", "listPosition" : 29, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437011, "link" : "/api/reference/437011", "label" : "30. Wang, C., Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia (2010) Curr. Opin. Urol, 20 (1), pp. 49-54. , http://dx.doi.org/10.1097/MOU.0b013e328333ac68, PMID: 19887943", "listPosition" : 30, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437010, "link" : "/api/reference/437010", "label" : "31. Jin, S.L., Ding, S.L., Lin, S.C., Phosphodiesterase 4 and its inhibitors in inflammatory diseases (2012) Chang Gung Med. J, 35 (3), pp. 197-210. , http://dx.doi.org/10.4103/2319-4170.106152, PMID: 22735051", "listPosition" : 31, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437009, "link" : "/api/reference/437009", "label" : "32. Rabe, K.F., Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease (2011) Br. J. Pharmacol, 163 (1), pp. 53-67. , http://dx.doi.org/10.1111/j.1476-5381.2011.01218.x, PMID: 21232047", "listPosition" : 32, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437008, "link" : "/api/reference/437008", "label" : "33. Yashiro, Y., Ohhashi, T., Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles (2002) Jpn. J. Physiol, 52 (5), pp. 471-477. , http://dx.doi.org/10.2170/jjphysiol.52.471, PMID: 12533252", "listPosition" : 33, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437007, "link" : "/api/reference/437007", "label" : "34. Movsesian, M.A., PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider (2003) J. Card. Fail, 9 (6), pp. 475-480. , http://dx.doi.org/10.1016/S1071-9164(03)00135-0, PMID: 14966789", "listPosition" : 34, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437006, "link" : "/api/reference/437006", "label" : "35. Masood, A., Huang, Y., Hajjhussein, H., Xiao, L., Li, H., Wang, W., Hamza, A., O’Donnell, J.M., Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling (2009) J. Pharmacol. Exp. Ther, 331 (2), pp. 690-699. , http://dx.doi.org/10.1124/jpet.109.156729, PMID: 19684253", "listPosition" : 35, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437005, "link" : "/api/reference/437005", "label" : "36. Boess, F.G., Hendrix, M., van der Staay, F-J., Erb, C., Schreiber, R., van Staveren, W., de Vente, J., Koenig, G., Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance (2004) Neuropharmacology, 47 (7), pp. 1081-1092. , http://dx.doi.org/10.1016/j.neuropharm.2004.07.040, PMID: 15555642", "listPosition" : 36, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437004, "link" : "/api/reference/437004", "label" : "37. Snyder, G.L., Prickaerts, J., Wadenberg, M.L., Zhang, L., Zheng, H., Yao, W., Akkerman, S., Wennogle, L.P., Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats (2016) Psychopharmacology (Berl.), 233 (17), pp. 3113-3124. , http://dx.doi.org/10.1007/s00213-016-4346-2, PMID: 27342643", "listPosition" : 37, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437003, "link" : "/api/reference/437003", "label" : "38. Chan, S., Yan, C., PDE1 isozymes, key regulators of pathological vascular remodeling (2011) Curr. Opin. Pharmacol, 11 (6), p. 720724. , http://dx.doi.org/10.1016/j.coph.2011.09.002, PMID: 21962439", "listPosition" : 38, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437002, "link" : "/api/reference/437002", "label" : "39. Grauer, S.M., Pulito, V.L., Navarra, R.L., Kelly, M.P., Kelley, C., Graf, R., Langen, B., Brandon, N.J., Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia (2009) J. Pharmacol. Exp. Ther, 331 (2), pp. 574-590. , http://dx.doi.org/10.1124/jpet.109.155994, PMID: 19661377", "listPosition" : 39, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437001, "link" : "/api/reference/437001", "label" : "40. Menniti, F.S., Chappie, T.A., Humphrey, J.M., Schmidt, C.J., Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia (2007) Curr. Opin. Investig. Drugs, 8 (1), pp. 54-59. , PMID: 17263185", "listPosition" : 40, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437000, "link" : "/api/reference/437000", "label" : "41. Conti, M., Beavo, J., Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling (2007) Annu. Rev. Biochem, 76, pp. 481-511. , http://dx.doi.org/10.1146/annurev.biochem.76.060305.150444, PMID: 17376027", "listPosition" : 41, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436999, "link" : "/api/reference/436999", "label" : "42. Gacci, M., Sebastianelli, A., Salvi, M., Vignozzi, L., Corona, G., McVary, K.T., Kaplan, S.A., Carini, M., PED5-Is for the Treatment of concomitant ED and LUTS/BPH (2013) Curr. Bladder Dysfunct. Rep, 8 (2), pp. 150-159. , http://dx.doi.org/10.1007/s11884-013-0184-9, PMID: 23888186", "listPosition" : 42, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436998, "link" : "/api/reference/436998", "label" : "43. Ejiofor, S., Turner, A.M., Pharmacotherapies for COPD (2013) Clin. Med. Insights Circ. Respir. Pulm. Med, 7, pp. 17-34. , http://dx.doi.org/10.4137/CCRPM.S7211, PMID: 23700381", "listPosition" : 43, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436997, "link" : "/api/reference/436997", "label" : "44. Eschenhagen, T., PDE4 in the human heart-major player or littel helper? (2013) BJP, 196 (3), pp. 524-527. , http://dx.doi.org/10.1111/bph.12168", "listPosition" : 44, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436996, "link" : "/api/reference/436996", "label" : "45. Bender, A.T., Beavo, J.A., Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use (2006) Pharmacol. Rev, 58 (3), pp. 488-520. , http://dx.doi.org/10.1124/pr.58.3.5, PMID: 16968949", "listPosition" : 45, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436995, "link" : "/api/reference/436995", "label" : "46. Maurice, D.H., Ke, H., Ahmad, F., Wang, Y., Chung, J., Manganiello, V.C., Advances in targeting cyclic nucleotide phosphodiesterases (2014) Nat. Rev. Drug Discov, 13 (4), pp. 290-314. , http://dx.doi.org/10.1038/nrd4228, PMID: 24687066", "listPosition" : 46, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436994, "link" : "/api/reference/436994", "label" : "47. Francis, S.H., Blount, M.A., Corbin, J.D., Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions (2011) Physiol. Rev, 91 (2), pp. 651-690. , http://dx.doi.org/10.1152/physrev.00030.2010, PMID: 21527734", "listPosition" : 47, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436993, "link" : "/api/reference/436993", "label" : "48. Tsai, E. J., Kass, D. A., Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics (2009) Pharmacol therapeut, 122 (3), pp. 216-238. , http://dx.doi.org/10.1016/j.pharmthera.2009.02.009", "listPosition" : 48, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436992, "link" : "/api/reference/436992", "label" : "49. Ahmad, F., Murata, T., Simizu, K., Degeman, E., Maurice, D., Manganiello, V., Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets (2015) Oral disease. PMC, 21 (1), pp. 25-50. , http://dx.doi.org/10.1111/odi.12275", "listPosition" : 49, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436991, "link" : "/api/reference/436991", "label" : "50. Li, Y-W., Seager, M.A., Wojcik, T., Heman, K., Molski, T.F., Fernandes, A., Langdon, S., Lodge, N.J., Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy (2016) Neuropharmacology, 102, pp. 121-135. , http://dx.doi.org/10.1016/j.neuropharm.2015.10.037, PMID: 26522433", "listPosition" : 50, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436990, "link" : "/api/reference/436990", "label" : "51. Kim, J.S., Kornhuber, H.H., Schmid-Burgk, W., Holzmüller, B., Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia (1980) Neurosci. Lett, 20 (3), p. 379382. , http://dx.doi.org/10.1016/0304-3940(80)90178-0, PMID: 6108541", "listPosition" : 51, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436989, "link" : "/api/reference/436989", "label" : "52. Coyle, J.T., The nagging question of the function of Nacetylaspartylglutamate (1997) Neurobiol. Dis, 4 (3-4), pp. 231-238. , http://dx.doi.org/10.1006/nbdi.1997.0153, PMID: 9361299", "listPosition" : 52, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436988, "link" : "/api/reference/436988", "label" : "53. IntechOpen: London", "listPosition" : 53, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436987, "link" : "/api/reference/436987", "label" : "54. Dagdeviren, M., Role of nitric oxide synthase in normal brain function and pathophysiology of neural diseases (2017) Nitric Oxide Synthase: Simple Enzyme-Complex Roles, , http://dx.doi.org/10.5772/67267, Saravi, S., Ed.", "listPosition" : 54, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436986, "link" : "/api/reference/436986", "label" : "55. Pitsikas, N., The role of nitric oxide in the object recognition memory (2015) Behav. Brain Res, 285, pp. 200-207. , http://dx.doi.org/10.1016/j.bbr.2014.06.008, PMID: 24933185", "listPosition" : 55, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436985, "link" : "/api/reference/436985", "label" : "56. Prast, H., Philippu, A., Nitric oxide as modulator of neuronal function (2001) Prog. Neurobiol, 64 (1), pp. 51-68. , http://dx.doi.org/10.1016/S0301-0082(00)00044-7, PMID: 11250062", "listPosition" : 56, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436984, "link" : "/api/reference/436984", "label" : "57. Huettner, J.E., Competitive antagonism of glycine at the N-methylD-aspartate (NMDA) receptor (1991) Biochem. Pharmacol, 41 (1), pp. 9-16. , http://dx.doi.org/10.1016/0006-2952(91)90004-O, PMID: 1824750", "listPosition" : 57, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436983, "link" : "/api/reference/436983", "label" : "58. Jentsch, J.D., Roth, R.H., The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia (1999) Neuropsychopharmacology, 20 (3), pp. 201-225. , http://dx.doi.org/10.1016/S0893-133X(98)00060-8, PMID: 10063482", "listPosition" : 58, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436982, "link" : "/api/reference/436982", "label" : "59. Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V., Di Filippo, M., Direct and indirect pathways of basal ganglia: a critical reappraisal (2014) Nat. Neurosci, 17 (8), pp. 1022-1030. , http://dx.doi.org/10.1038/nn.3743, PMID: 25065439", "listPosition" : 59, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436981, "link" : "/api/reference/436981", "label" : "60. Kravitz, A.V., Freeze, B.S., Parker, P.R., Kay, K., Thwin, M.T., Deisseroth, K., Kreitzer, A.C., Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry (2010) Nature, 466 (7306), pp. 622-626. , http://dx.doi.org/10.1038/nature09159, PMID: 20613723", "listPosition" : 60, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436980, "link" : "/api/reference/436980", "label" : "61. Abercrombie, E.D., DeBoer, P., Substantia nigra D1 receptors and stimulation of striatal cholinergic interneurons by dopamine: a proposed circuit mechanism (1997) J. Neurosci, 17 (21), pp. 8498-8505. , http://dx.doi.org/10.1523/JNEUROSCI.17-21-08498.1997, PMID: 9334422", "listPosition" : 61, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436979, "link" : "/api/reference/436979", "label" : "62. Gerfen, C.R., Molecular effects of dopamine on striatal-projection pathways (2000) Trends Neurosci, 23 (10), pp. S64-S70. , http://dx.doi.org/10.1016/S1471-1931(00)00019-7, (Suppl), PMID: 11052222", "listPosition" : 62, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436978, "link" : "/api/reference/436978", "label" : "63. Gerfen, C.R., McGinty, J.F., Young, W.S., Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis (1991) J. Neurosci, 11 (4), pp. 1016-1031. , http://dx.doi.org/10.1523/JNEUROSCI.11-04-01016.1991, PMID: 1707092", "listPosition" : 63, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436977, "link" : "/api/reference/436977", "label" : "64. Parent, A., Hazrati, L.N., Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop (1995) Brain Res. Brain Res. Rev, 20 (1), pp. 91-127. , http://dx.doi.org/10.1016/0165-0173(94)00007-C, PMID: 7711769", "listPosition" : 64, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436976, "link" : "/api/reference/436976", "label" : "65. Gerfen, C.R., The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia (1992) Annu. Rev. Neurosci, 15, pp. 285-320. , http://dx.doi.org/10.1146/annurev.ne.15.030192.001441, PMID: 1575444", "listPosition" : 65, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436975, "link" : "/api/reference/436975", "label" : "66. Tepper, J.M., Abercrombie, E.D., Bolam, J.P., Basal ganglia macrocircuits (2007) Prog. Brain Res, 160, pp. 3-7. , http://dx.doi.org/10.1016/S0079-6123(06)60001-0, PMID: 17499105", "listPosition" : 66, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436974, "link" : "/api/reference/436974", "label" : "67. Smith, Y., Bevan, M.D., Shink, E., Bolam, J.P., Microcircuitry of the direct and indirect pathways of the basal ganglia (1998) Neuroscience, 86 (2), pp. 353-387. , PMID: 9881853", "listPosition" : 67, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436973, "link" : "/api/reference/436973", "label" : "68. Hedreen, J.C., DeLong, M.R., Organization of striatopallidal, striatonigral, and nigrostriatal projections in the macaque (1991) J. Comp. Neurol, 304 (4), pp. 569-595. , http://dx.doi.org/10.1002/cne.903040406, PMID: 2013650", "listPosition" : 68, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436972, "link" : "/api/reference/436972", "label" : "69. Graveland, G.A., DiFiglia, M., The frequency and distribution of medium-sized neurons with indented nuclei in the primate and rodent neostriatum (1985) Brain Res, 327 (1-2), pp. 307-311. , http://dx.doi.org/10.1016/0006-8993(85)91524-0, PMID: 3986508", "listPosition" : 69, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436971, "link" : "/api/reference/436971", "label" : "70. Björklund, A., Dunnett, S.B., Dopamine neuron systems in the brain: an update (2007) Trends Neurosci, 30 (5), pp. 194-202. , http://dx.doi.org/10.1016/j.tins.2007.03.006, PMID: 17408759", "listPosition" : 70, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436970, "link" : "/api/reference/436970", "label" : "71. Alexander, G.E., Crutcher, M.D., DeLong, M.R., Basal gangliathalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions (1990) Prog. Brain Res, 85, pp. 119-146. , http://dx.doi.org/10.1016/S0079-6123(08)62678-3, PMID: 2094891", "listPosition" : 71, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436969, "link" : "/api/reference/436969", "label" : "72. Alexander, G.E., DeLong, M.R., Strick, P.L., Parallel organization of functionally segregated circuits linking basal ganglia and cortex (1986) Annu. Rev. Neurosci, 9, pp. 357-381. , http://dx.doi.org/10.1146/annurev.ne.09.030186.002041, PMID: 3085570", "listPosition" : 72, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436968, "link" : "/api/reference/436968", "label" : "73. Luo, S.X., Huang, E.J., Dopaminergic Neurons and Brain Reward Pathways: From Neurogenesis to Circuit Assembly (2016) Am. J. Pathol, 186 (3), pp. 478-488. , http://dx.doi.org/10.1016/j.ajpath.2015.09.023, PMID: 26724386", "listPosition" : 73, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436967, "link" : "/api/reference/436967", "label" : "74. Perez-Costas, E., Melendez-Ferro, M., Roberts, R.C., Basal ganglia pathology in schizophrenia: dopamine connections and anomalies (2010) J. Neurochem, 113 (2), pp. 287-302. , http://dx.doi.org/10.1111/j.1471-4159.2010.06604.x, PMID: 20089137", "listPosition" : 74, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436966, "link" : "/api/reference/436966", "label" : "75. Howes, O.D., Kapur, S., The dopamine hypothesis of schizophrenia: version III--the final common pathway (2009) Schizophr. Bull, 35 (3), pp. 549-562. , http://dx.doi.org/10.1093/schbul/sbp006, PMID: 19325164", "listPosition" : 75, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436965, "link" : "/api/reference/436965", "label" : "76. Kehler, J., Nielsen, J., PDE10A inhibitors: novel therapeutic drugs for schizophrenia (2011) Curr. Pharm. Des, 17 (2), pp. 137-150. , http://dx.doi.org/10.2174/138161211795049624, PMID: 21355834", "listPosition" : 76, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436964, "link" : "/api/reference/436964", "label" : "77. Tsapakis, E.M., Dimopoulou, T., Tarazi, F.I., Clinical management of negative symptoms of schizophrenia: An update (2015) Pharmacol. Ther, 153, pp. 135-147. , http://dx.doi.org/10.1016/j.pharmthera.2015.06.008, PMID: 26116809", "listPosition" : 77, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436963, "link" : "/api/reference/436963", "label" : "78. Siuciak, J.A., Chapin, D.S., Harms, J.F., Lebel, L.A., McCarthy, S.A., Chambers, L., Shrikhande, A., Schmidt, C.J., Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis (2006) Neuropharmacology, 51 (2), pp. 386-396. , http://dx.doi.org/10.1016/j.neuropharm.2006.04.013, PMID: 16780899", "listPosition" : 78, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436962, "link" : "/api/reference/436962", "label" : "79. Mattson, M.P., Chan, S.L., Duan, W., Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior (2002) Physiol. Rev, 82 (3), pp. 637-672. , http://dx.doi.org/10.1152/physrev.00004.2002, PMID: 12087131", "listPosition" : 79, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436961, "link" : "/api/reference/436961", "label" : "80. Bubl, E., Werner, L., Liang, Y., Ebert, D., Friedel, E., Bubl, A., Bach, M., van Elst, L.T., Evaluating the neurobiological correlations and impact of treatment on cognitive dysfunction in ADHA and schizophrenia by means of the pattern electroretinogram (2018) Schizophr. Bull, p. 44", "listPosition" : 80, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436960, "link" : "/api/reference/436960", "label" : "81. Lyne, J., Renwick, L., O’Donoghue, B., Kinsella, A., Malone, K., Turner, N., O’Callaghan, E., Clarke, M., Negative symptom domain prevalence across diagnostic boundaries: The relevance of diagnostic shifts (2015) Psychiatry Res, 228 (3), pp. 347-354. , http://dx.doi.org/10.1016/j.psychres.2015.05.086, PMID: 26162655", "listPosition" : 81, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436959, "link" : "/api/reference/436959", "label" : "82. Bobes, J., Arango, C., Garcia-Garcia, M., Rejas, J., Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study (2010) J. Clin. Psychiatry, 71 (3), pp. 280-286. , http://dx.doi.org/10.4088/JCP.08m04250yel, CLAMORS Study Collaborative Group. PMID: 19895779", "listPosition" : 82, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436958, "link" : "/api/reference/436958", "label" : "83. Kirschner, M., Aleman, A., Kaiser, S., Secondary negative symptoms-A review of mechanisms, assessment and treatment (2017) Schizophr. Res, 186, pp. 29-38. , http://dx.doi.org/10.1016/j.schres.2016.05.003, PMID: 27230288", "listPosition" : 83, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436957, "link" : "/api/reference/436957", "label" : "84. Remington, G., Foussias, G., Fervaha, G., Agid, O., Takeuchi, H., Lee, J., Hahn, M., Treating negative symptoms in schizophrenia: An Update (2016) Curr. Treat. Options Psychiatry, 3, pp. 133-150. , http://dx.doi.org/10.1007/s40501-016-0075-8, PMID: 27376016", "listPosition" : 84, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436956, "link" : "/api/reference/436956", "label" : "85. Kirkpatrick, B., Buchanan, R.W., Ross, D.E., Carpenter, W.T., A separate disease within the syndrome of schizophrenia (2001) Arch. Gen. Psychiatry, 58 (2), pp. 165-171. , http://dx.doi.org/10.1001/archpsyc.58.2.165, PMID: 11177118", "listPosition" : 85, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436955, "link" : "/api/reference/436955", "label" : "86. Carbon, M., Correll, C.U., Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia (2014) CNS Spectr, 19, pp. 38-52. , http://dx.doi.org/10.1017/S1092852914000601, (Suppl. 1), PMID: 25403863", "listPosition" : 86, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 436954, "link" : "/api/reference/436954", "label" : "87. Kaneko, K., Negative Symptoms and cognitive impairments in schizophrenia: two key symptoms negatively influencing social functioning (2018) Yonago Acta Med, 61 (2), pp. 91-102. , http://dx.doi.org/10.33160/yam.2018.06.001, PMID: 29946215", "listPosition" : 87, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437127, "link" : "/api/reference/437127", "label" : "88. Hankir, M.K., Kranz, M., Gnad, T., Weiner, J., Wagner, S., Deuther-Conrad, W., Bronisch, F., Fenske, W.K., A novel thermoregulatory role for PDE10A in mouse and human adipocytes (2016) EMBO Mol. Med, 8 (7), pp. 796-812. , http://dx.doi.org/10.15252/emmm.201506085, PMID: 27247380", "listPosition" : 88, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437126, "link" : "/api/reference/437126", "label" : "89. Clinical trial study found in clinical trials for Pf-02545920: NCT02342548, , https://www.clinicaltrials.gov/ct2/show/NCT02342548, (Accessed April 26, 2020)", "listPosition" : 89, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437125, "link" : "/api/reference/437125", "label" : "90. Giampà, C., Laurenti, D., Anzilotti, S., Bernardi, G., Menniti, F.S., Fusco, F.R., Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington’s disease (2010) PLoS One, 5 (10), p. e13417. , http://dx.doi.org/10.1371/journal.pone.0013417, PMID: 20976216", "listPosition" : 90, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437124, "link" : "/api/reference/437124", "label" : "91. https://www.clinicaltrials.gov/ct2/show/NCT00930059, Clinical trial study found in clinical trials for PF-04447943: NCT00930059 (Accessed April 26, 2020)", "listPosition" : 91, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437123, "link" : "/api/reference/437123", "label" : "92. Shao, Y.X., Huang, M., Cui, W., Feng, L-J., Wu, Y., Cai, Y., Li, Z., Luo, H.B., Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent (2014) J. Med. Chem, 57 (24), pp. 10304-10313. , http://dx.doi.org/10.1021/jm500836h, PMID: 25432025", "listPosition" : 92, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437122, "link" : "/api/reference/437122", "label" : "93. Keating, G.M., Apremilast: a review in psoriasis and psoriatic arthritis (2017) Drugs, 77 (4), pp. 459-472. , http://dx.doi.org/10.1007/s40265-017-0709-1, PMID: 28213862", "listPosition" : 93, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437121, "link" : "/api/reference/437121", "label" : "94. Phillips, J.E., Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for inflammatory respiratory diseases (2020) Front. Pharmacol, 11, p. 259. , http://dx.doi.org/10.3389/fphar.2020.00259, PMID: 32226383", "listPosition" : 94, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437120, "link" : "/api/reference/437120", "label" : "95. Houslay, M.D., Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown (2010) Trends Biochem. Sci, 35 (2), pp. 91-100. , http://dx.doi.org/10.1016/j.tibs.2009.09.007, PMID: 19864144", "listPosition" : 95, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437119, "link" : "/api/reference/437119", "label" : "96. Clinical trial study found in clinical trials for PF-05180999: NCT01981499, , https://clinicaltrials.gov/ct2/show/NCT01981499, (Accessed April 26, 2020)", "listPosition" : 96, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437118, "link" : "/api/reference/437118", "label" : "97. Clinical trial study found in clinical trials for PF-05180999: NCT01981486, , https://clinicaltrials.gov/ct2/show/NCT01981486, (Accessed April 26, 2020)", "listPosition" : 97, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437117, "link" : "/api/reference/437117", "label" : "98. Prickaerts, J., Heckman, P.R.A., Blokland, A., Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease (2017) Expert Opin. Investig. Drugs, 26 (9), pp. 1033-1048. , http://dx.doi.org/10.1080/13543784.2017.1364360, PMID: 28772081", "listPosition" : 98, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437116, "link" : "/api/reference/437116", "label" : "99. Zhang, C., Yu, Y., Ruan, L., Wang, C., Pan, J., Klabnik, J., Lueptow, L., Xu, Y., The roles of phosphodiesterase 2 in the central nervous and peripheral systems (2015) Curr. Pharm. Des, 21 (3), pp. 274-290. , http://dx.doi.org/10.2174/1381612820666140826115245, PMID: 25159070", "listPosition" : 99, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437115, "link" : "/api/reference/437115", "label" : "100. Clinical trial study found in clinical trials for ITI-214, , https://clinicaltrials.gov/ct2/show/NCT03387215, NCT03387215 (Accessed April 24, 2020)", "listPosition" : 100, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437114, "link" : "/api/reference/437114", "label" : "101. Clinical trial study found in clinical trials for ITI-214: NCT03257046, , https://clinicaltrials.gov/ct2/show/NCT03257046, (Accessed April 24, 2020)", "listPosition" : 101, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437113, "link" : "/api/reference/437113", "label" : "102. Hashimoto, T., Kim, G.E., Tunin, R.S., Adesiyun, T., Hsu, S., Nakagawa, R., Zhu, G., Kass, D.A., Acute enhancement of cardiac function by phosphodiesterase type 1 inhibition: translational study in the dog and rabbit (2018) Circulation, 138 (18), pp. 1974-1987. , http://dx.doi.org/10.1161/CIRCULATIONAHA.117.030490, PMID: 30030415", "listPosition" : 102, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437112, "link" : "/api/reference/437112", "label" : "103. Cardinale, A., Fusco, F.R., Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington’s disease (2018) CNS Neurosci. Ther, 24 (4), pp. 319-328. , http://dx.doi.org/10.1111/cns.12834, PMID: 29500937", "listPosition" : 103, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437111, "link" : "/api/reference/437111", "label" : "104. Chen, S., Knight, W.E., Yan, C., Roles of PDE1 in pathological cardiac remodeling and dysfunction (2018) J. Cardiovasc. Dev. Dis, 5 (2), p. 22. , http://dx.doi.org/10.3390/jcdd5020022, PMID: 29690591", "listPosition" : 104, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437110, "link" : "/api/reference/437110", "label" : "105. Clinical trial study found in clinical trials for EVP-6308: NCT02037074, , https://clinicaltrials.gov/ct2/show/NCT02037074, (Accessed October 31, 2019)", "listPosition" : 105, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437109, "link" : "/api/reference/437109", "label" : "106. Clinical trial study found in clinical trials for OMS643762: NCT01952132, , https://clinicaltrials.gov/ct2/show/NCT01952132, (Accessed October 31, 2019)", "listPosition" : 106, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437108, "link" : "/api/reference/437108", "label" : "107. (2014) Omeros Reports Positive Results from New Medication Phase 2 Clinical Trial for Schizophrenia, , http://schizophrenia.com/?p=40, Schizophrenia.com. (Accessed October 31, 2019)", "listPosition" : 107, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437107, "link" : "/api/reference/437107", "label" : "108. Kunitomo, J., Yoshikawa, M., Fushimi, M., Kawada, A., Quinn, J.F., Oki, H., Kokubo, H., Taniguchi, T., Discovery of 1-[2-fluoro4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor (2014) J. Med. Chem, 57 (22), pp. 9627-9643. , http://dx.doi.org/10.1021/jm5013648, PMID: 25384088", "listPosition" : 108, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437106, "link" : "/api/reference/437106", "label" : "109. Macek, T.A., McCue, M., Dong, X., Hanson, E., Goldsmith, P., Affinito, J., Mahableshwarkar, A.R., A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia (2019) Schizophr. Res, 204, pp. 289-294. , http://dx.doi.org/10.1016/j.schres.2018.08.028, PMID: 30190165", "listPosition" : 109, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437105, "link" : "/api/reference/437105", "label" : "110. Shiraishi, E., Suzuki, K., Harada, A., Suzuki, N., Kimura, H., The phosphodiesterase 10a selective inhibitor tak-063 improves cognitive functions associated with schizophrenia in rodent models (2016) J. Pharmacol. Exp. Ther, 356 (3), pp. 587-595. , http://dx.doi.org/10.1124/jpet.115.230482, PMID: 26675680", "listPosition" : 110, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437104, "link" : "/api/reference/437104", "label" : "111. DeMartinis, N., Banerjee, A., Kumar, V., Boyer, S., Schmidt, C., Arroyo, S., Results of a phase 2a proof-of-concept trial with a PDE10A Inhibitor in the treatment of acute exacerbation of schizophrenia (2012) Schizophr. Res, 136, p. S262. , http://dx.doi.org/10.1016/S0920-9964(12)70783-1", "listPosition" : 111, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437103, "link" : "/api/reference/437103", "label" : "112. Suzuki, K., Harada, A., Suzuki, H., Miyamoto, M., Kimura, H., TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms (2016) Neuropsychopharmacology, 41 (9), p. 22522262. , http://dx.doi.org/10.1038/npp.2016.20, PMID: 26849714", "listPosition" : 112, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437102, "link" : "/api/reference/437102", "label" : "113. Zagorska, A., Partyka, A., Bucki, A., Gawalskax, A., Czopek, A., Pawlowski, M., Phosphodiesterase 10 inhibitors-novel perspectives for psychiatric and neurodegenerative drug discovery (2018) Curr. Med. Chem, 25 (29), pp. 3455-3481. , http://dx.doi.org/10.2174/0929867325666180309110629, PMID: 29521210", "listPosition" : 113, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437101, "link" : "/api/reference/437101", "label" : "114. Rodefer, J.S., Murphy, E.R., Baxter, M.G., PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats (2005) Eur. J. Neurosci, 21 (4), pp. 1070-1076. , http://dx.doi.org/10.1111/j.1460-9568.2005.03937.x, PMID: 15787711", "listPosition" : 114, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437100, "link" : "/api/reference/437100", "label" : "115. Hollman, A., Bank, S., Pett, C.H., Plants and the heart windfalls from the opium poppy: the discovery of papaverine and verapamil (2005) Dialogues Cardiovasc. Med, 10, pp. 259-263", "listPosition" : 115, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437099, "link" : "/api/reference/437099", "label" : "116. Baumeister, A.A., Francis, J.L., Historical development of the dopamine hypothesis of schizophrenia (2002) J. Hist. Neurosci, 11 (3), pp. 265-277. , http://dx.doi.org/10.1076/jhin.11.3.265.10391, PMID: 12481477", "listPosition" : 116, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437098, "link" : "/api/reference/437098", "label" : "117. Nishi, A., Kuroiwa, M., Miller, D.B., O’Callaghan, J.P., Bateup, H.S., Shuto, T., Sotogaku, N., Snyder, G.L., Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum (2008) J. Neurosci, 28 (42), pp. 10460-10471. , http://dx.doi.org/10.1523/JNEUROSCI.2518-08.2008, PMID: 18923023", "listPosition" : 117, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437097, "link" : "/api/reference/437097", "label" : "118. Fujishige, K., Kotera, J., Omori, K., Striatum-and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A (1999) Eur. J. Biochem, 266 (3), pp. 1118-1127. , http://dx.doi.org/10.1046/j.1432-1327.1999.00963.x, PMID: 10583409", "listPosition" : 118, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437096, "link" : "/api/reference/437096", "label" : "119. Ooms, M., Attili, B., Celen, S., Koole, M., Verbruggen, A., Van Laere, K., Bormans, G., [18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP (2016) J. Neurochem, 139 (5), pp. 897-906. , http://dx.doi.org/10.1111/jnc.13855, PMID: 27664396", "listPosition" : 119, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437095, "link" : "/api/reference/437095", "label" : "120. Bateup, H.S., Svenningsson, P., Kuroiwa, M., Gong, S., Nishi, A., Heintz, N., Greengard, P., Cell type-specific regulation of DARPP32 phosphorylation by psychostimulant and antipsychotic drugs (2008) Nat. Neurosci, 11 (8), pp. 932-939. , http://dx.doi.org/10.1038/nn.2153, PMID: 18622401", "listPosition" : 120, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437094, "link" : "/api/reference/437094", "label" : "121. Xie, Z., Adamowicz, W.O., Eldred, W.D., Jakowski, A.B., Kleiman, R.J., Morton, D.G., Stephenson, D.T., Menniti, F.S., Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase (2006) Neuroscience, 139 (2), pp. 597-607. , http://dx.doi.org/10.1016/j.neuroscience.2005.12.042, PMID: 16483723", "listPosition" : 121, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437093, "link" : "/api/reference/437093", "label" : "122. https://clinicaltrials.gov/ct2/show/results/NCT02281773, Clinical trial study found in clinical trials for BI 409306: NCT02281773. (Accessed February 4, 2020)", "listPosition" : 122, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437092, "link" : "/api/reference/437092", "label" : "123. Verhoest, P.R., Fonseca, K.R., Hou, X., Proulx-Lafrance, C., Corman, M., Helal, C.J., Claffey, M.M., Liras, S., Design and discovery of 6-[(3S,4S)4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders (2012) J. Med. Chem, 55 (21), pp. 9045-9054. , http://dx.doi.org/10.1021/jm3007799, PMID: 22780914", "listPosition" : 123, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437091, "link" : "/api/reference/437091", "label" : "124. Li, J., Liu, C-N., Wei, N., Li, X-D., Liu, Y-Y., Yang, R., Jia, Y-J., Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-β peptides-induced oxidative stress in in-vivo and in-vitro models of Alzheimer’s disease (2016) Brain Res, 1642, pp. 327-335. , http://dx.doi.org/10.1016/j.brainres.2016.04.011, PMID: 27071547", "listPosition" : 124, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437090, "link" : "/api/reference/437090", "label" : "125. van der Staay, F.J., Rutten, K., Bärfacker, L., Devry, J., Erb, C., Heckroth, H., Karthaus, D., Hendrix, M., The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents (2008) Neuropharmacology, 55 (5), pp. 908-918. , http://dx.doi.org/10.1016/j.neuropharm.2008.07.005, PMID: 18674549", "listPosition" : 125, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437089, "link" : "/api/reference/437089", "label" : "126. Andreeva, S.G., Dikkes, P., Epstein, P.M., Rosenberg, P.A., Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain (2001) J. Neurosci, 21 (22), pp. 9068-9076. , http://dx.doi.org/10.1523/JNEUROSCI.21-22-09068.2001, PMID: 11698617", "listPosition" : 126, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437088, "link" : "/api/reference/437088", "label" : "127. Soderling, S.H., Bayuga, S.J., Beavo, J.A., Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases (1998) J. Biol. Chem, 273 (25), pp. 15553-15558. , http://dx.doi.org/10.1074/jbc.273.25.15553, PMID: 9624145", "listPosition" : 127, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437087, "link" : "/api/reference/437087", "label" : "128. Fisher, D.A., Smith, J.F., Pillar, J.S., St Denis, S.H., Cheng, J.B., Isolation and characterization of PDE9A, a novel human cGMPspecific phosphodiesterase (1998) J. Biol. Chem, 273 (25), p. 1555915564. , http://dx.doi.org/10.1074/jbc.273.25.15559, PMID: 9624146", "listPosition" : 128, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437086, "link" : "/api/reference/437086", "label" : "129. Clinical trial study found in clinical trials for Etazolate: NCT00880412, , https://clinicaltrials.gov/ct2/show/NCT00880412, (Accessed November 4, 2019)", "listPosition" : 129, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437085, "link" : "/api/reference/437085", "label" : "130. https://clinicaltrials.gov/ct2/show/NCT03030105, Clinical trial study found in clinical trials for BPN14770: NCT03030105. (Accessed November 1, 2019)", "listPosition" : 130, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437084, "link" : "/api/reference/437084", "label" : "131. Clinical trial study found in clinical trials for HT-0712: NCT02013310, , https://clinicaltrials.gov/ct2/show/NCT02013310, (Accessed November 4, 2019)", "listPosition" : 131, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437083, "link" : "/api/reference/437083", "label" : "132. Clinical trial study found in clinical trials for Roflumilast, , https://clinicaltrials.gov/ct2/show/NCT01433666, NCT01433666 (Accessed November 4, 2019)", "listPosition" : 132, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437082, "link" : "/api/reference/437082", "label" : "133. Gilleen, J., Farah, Y., Davison, C., Kerins, S., Valdearenas, L., Uz, T., Lahu, G., Shergill, S.S., An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memoryrelated brain activity and episodic memory in schizophrenia patients (2018) Psychopharmacology (Berl.), , http://dx.doi.org/10.1007/s00213-018-5134-y, (ePub ahead of print) PMID: 30536081", "listPosition" : 133, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437081, "link" : "/api/reference/437081", "label" : "134. Van Duinen, M.A., Heckman, P.R.A., Vanmierlo, T., Sambeth, A., Ogrinc, F., Tsai, M., Lahu, G., Prickaerts, J., The PDE4-inhbitor roflumilast improves episodic memory: findings from a translational perspective (2017) Eur. Neuropsychopharmacol, 27, pp. S1024-S1025. , http://dx.doi.org/10.1016/S0924-977X(17)31794-7", "listPosition" : 134, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437080, "link" : "/api/reference/437080", "label" : "135. Van Duinen, M.A., Sambeth, A., Heckman, P.R.A., Smit, S., Tsai, M., Lahu, G., Uz, T., Prickaerts, J., Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults (2018) Neuropharmacology, 131, pp. 31-38. , http://dx.doi.org/10.1016/j.neuropharm.2017.12.019, PMID: 29241652", "listPosition" : 135, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437079, "link" : "/api/reference/437079", "label" : "136. Vanmierlo, T., Creemers, P., Akkerman, S., van Duinen, M., Sambeth, A., De Vry, J., Uz, T., Prickaerts, J., The PDE4 inhibitor roflumilast improves memory in rodents at nonemetic doses (2016) Behav. Brain Res, 303, pp. 26-33. , http://dx.doi.org/10.1016/j.bbr.2016.01.031, PMID: 26794595", "listPosition" : 136, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437078, "link" : "/api/reference/437078", "label" : "137. Mori, F., Pérez-Torres, S., De Caro, R., Porzionato, A., Macchi, V., Beleta, J., Gavaldà, A., Mengod, G., The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D (2010) J. Chem. Neuroanat, 40 (1), pp. 36-42. , http://dx.doi.org/10.1016/j.jchemneu.2010.03.004, PMID: 20347962", "listPosition" : 137, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437077, "link" : "/api/reference/437077", "label" : "138. Krause, W., Kühne, G., Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences (1988) Xenobiotica, 18 (5), pp. 561-571. , http://dx.doi.org/10.3109/00498258809041693, PMID: 3400274", "listPosition" : 138, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437076, "link" : "/api/reference/437076", "label" : "139. Zhang, H.T., O’Donnell, J.M., Effects of rolipram on scopolamineinduced impairment of working and reference memory in the radialarm maze tests in rats (2000) Psychopharmacology (Berl.), 150 (3), pp. 311-316. , http://dx.doi.org/10.1007/s002130000414, PMID: 10923759", "listPosition" : 139, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437075, "link" : "/api/reference/437075", "label" : "140. Bruno, O., Fedele, E., Prickaerts, J., Parker, L.A., Canepa, E., Brullo, C., Cavallero, A., Ricciarelli, R., GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses (2011) Br. J. Pharmacol, 164 (8), pp. 2054-2063. , http://dx.doi.org/10.1111/j.1476-5381.2011.01524.x, PMID: 21649644", "listPosition" : 140, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437074, "link" : "/api/reference/437074", "label" : "141. Burgin, A.B., Magnusson, O.T., Singh, J., Witte, P., Staker, B.L., Bjornsson, J.M., Thorsteinsdottir, M., Gurney, M.E., Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety (2010) Nat. Biotechnol, 28 (1), p. 6370. , http://dx.doi.org/10.1038/nbt.1598, PMID: 20037581", "listPosition" : 141, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437073, "link" : "/api/reference/437073", "label" : "142. Taylor, J.R., Birnbaum, S., Ubriani, R., Arnsten, A.F., Activation of cAMP-dependent protein kinase A in prefrontal cortex impairs working memory performance (1999) J. Neurosci, 19 (18), p. RC23. , http://dx.doi.org/10.1523/JNEUROSCI.19-18-j0001.1999, PMID: 10479716", "listPosition" : 142, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437072, "link" : "/api/reference/437072", "label" : "143. Goldman-Rakic, P.S., Castner, S.A., Svensson, T.H., Siever, L.J., Williams, G.V., Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction (2004) Psychopharmacology (Berl.), 174 (1), pp. 3-16. , http://dx.doi.org/10.1007/s00213-004-1793-y, PMID: 15118803", "listPosition" : 143, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437071, "link" : "/api/reference/437071", "label" : "144. Heinrichs, R.W., Zakzanis, K.K., Neurocognitive deficit in schizophrenia: a quantitative review of the evidence (1998) Neuropsychology, 12 (3), pp. 426-445. , http://dx.doi.org/10.1037/0894-4105.12.3.426, PMID: 9673998", "listPosition" : 144, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437070, "link" : "/api/reference/437070", "label" : "145. Kuroiwa, M., Snyder, G.L., Shuto, T., Fukuda, A., Yanagawa, Y., Benavides, D.R., Nairn, A.C., Nishi, A., Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex (2012) Psychopharmacology (Berl.), 219 (4), pp. 1065-1079. , http://dx.doi.org/10.1007/s00213-011-2436-8, PMID: 21833500", "listPosition" : 145, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437069, "link" : "/api/reference/437069", "label" : "146. McGirr, A., Lipina, T.V., Mun, H.S., Georgiou, J., Al-Amri, A.H., Ng, E., Zhai, D., Roder, J.C., Specific inhibition of phosphodiesterase-4B results in anxiolysis and facilitates memory acquisition (2016) Neuropsychopharmacology, 41 (4), pp. 1080-1092. , http://dx.doi.org/10.1038/npp.2015.240, PMID: 26272049", "listPosition" : 146, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437068, "link" : "/api/reference/437068", "label" : "147. Wise, R.A., Dopamine, learning and motivation (2004) Nat. Rev. Neurosci, 5 (6), pp. 483-494. , http://dx.doi.org/10.1038/nrn1406, PMID: 15152198", "listPosition" : 147, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437067, "link" : "/api/reference/437067", "label" : "148. 2-R, PMID: 10213096", "listPosition" : 148, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437066, "link" : "/api/reference/437066", "label" : "149. Cherry, J.A., Davis, R.L., Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect (1999) J. Comp. Neurol, 407 (2), pp. 287-301. , http://dx.doi.org/10.1002/(SICI)10969861(19990503)407:2<287::AID-CNE9>3.0.CO", "listPosition" : 149, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437065, "link" : "/api/reference/437065", "label" : "150. Richter, W., Menniti, F.S., Zhang, H.T., Conti, M., PDE4 as a target for cognition enhancement (2013) Expert Opin. Ther. Targets, 17 (9), pp. 1011-1027. , http://dx.doi.org/10.1517/14728222.2013.818656, PMID: 23883342", "listPosition" : 150, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437064, "link" : "/api/reference/437064", "label" : "151. Clinical trial study found in clinical trials for TAK-915: NCT02461160, , https://clinicaltrials.gov/ct2/show/NCT02461160, (Accessed February 5, 2020)", "listPosition" : 151, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437063, "link" : "/api/reference/437063", "label" : "152. Clinical trial study found in clinical trials for TAK-915: NCT02584569, , https://clinicaltrials.gov/ct2/show/NCT02584569, (Accessed February 5, 2020)", "listPosition" : 152, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437062, "link" : "/api/reference/437062", "label" : "153. Gomez, L., Breitenbucher, J.G., PDE2 inhibition: potential for the treatment of cognitive disorders (2013) Bioorg. Med. Chem. Lett, 23 (24), pp. 6522-6527. , http://dx.doi.org/10.1016/j.bmcl.2013.10.014, PMID: 24189054", "listPosition" : 153, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437061, "link" : "/api/reference/437061", "label" : "154. design and parallel chemistry to identify a potent, selective, and brain penetrant Phosphodiesterase 2A inhibitor (2017) J. Med. Chem, 60 (13), pp. 5673-5698. , http://dx.doi.org/10.1021/acs.jmedchem.7b00397, PMID: 28574706", "listPosition" : 154, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437060, "link" : "/api/reference/437060", "label" : "155. Helal, C.J., Arnold, E.P., Boyden, T.L., Chang, C., Chappie, T.A., Fennell, K.F., Forman, M.D., Yang, E.X., Application of structure-based", "listPosition" : 155, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437059, "link" : "/api/reference/437059", "label" : "156. Clinical trial study found in clinical trials for PF-05180999, , https://clinicaltrials.gov/ct2/show/NCT01530529, NCT01530529 (Accessed February 5, 2020)", "listPosition" : 156, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437058, "link" : "/api/reference/437058", "label" : "157. Clinical trial study found in clinical trials for PF-05180999: NCT01429740, , https://clinicaltrials.gov/ct2/show/NCT01429740, (Accessed February 5, 2020)", "listPosition" : 157, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437057, "link" : "/api/reference/437057", "label" : "158. Fernández-Fernández, D., Rosenbrock, H., Kroker, K.S., Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus (2015) Synapse, 69 (10), pp. 484-496. , http://dx.doi.org/10.1002/syn.21840, PMID: 26178667", "listPosition" : 158, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437056, "link" : "/api/reference/437056", "label" : "159. Springer: Berlin", "listPosition" : 159, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437055, "link" : "/api/reference/437055", "label" : "160. O’Donnell, J.M., Eds.", "listPosition" : 160, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437054, "link" : "/api/reference/437054", "label" : "161. Xu, Y.", "listPosition" : 161, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437053, "link" : "/api/reference/437053", "label" : "162. Snyder, G.L., Vanover, K.E., (2017) PDE Inhibitors for the Treatment of Schizophrenia.Phosphodiesterases: CNS Functions and Diseases, pp. 385-409. , http://dx.doi.org/10.1007/978-3-319-58811-7_14, Zhang, H.T.", "listPosition" : 162, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437052, "link" : "/api/reference/437052", "label" : "163. Reneerkens, O.A.H., Rutten, K., Bollen, E., Hage, T., Blokland, A., Steinbusch, H.W.M., Prickaerts, J., Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801 (2013) Behav. Brain Res, 236 (1), pp. 16-22. , http://dx.doi.org/10.1016/j.bbr.2012.08.019, PMID: 22951181", "listPosition" : 163, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437051, "link" : "/api/reference/437051", "label" : "164. Domek-Łopacińska, K., Strosznajder, J.B., The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging (2008) Brain Res, 1216, pp. 68-77. , http://dx.doi.org/10.1016/j.brainres.2008.02.108, PMID: 18499090", "listPosition" : 164, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437050, "link" : "/api/reference/437050", "label" : "165. Rutten, K., Prickaerts, J., Hendrix, M., van der Staay, F.J., Şik, A., Blokland, A., Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors (2007) Eur. J. Pharmacol, 558 (1-3), pp. 107-112. , http://dx.doi.org/10.1016/j.ejphar.2006.11.041, PMID: 17207788", "listPosition" : 165, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437049, "link" : "/api/reference/437049", "label" : "166. Wu, Y., Li, Z., Huang, Y-Y., Wu, D., Luo, H-B., Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer’s Disease (2018) J. Med. Chem, 61 (13), pp. 5467-5483. , http://dx.doi.org/10.1021/acs.jmedchem.7b01370, PMID: 29363967", "listPosition" : 166, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437048, "link" : "/api/reference/437048", "label" : "167. Abdel-Magid, A.F., Potential treatment of cognitive impairment in schizophrenia by phosphodiesterase 2 (PDE2) inhibitors (2016) ACS Med. Chem. Lett, 8 (1), pp. 17-18. , http://dx.doi.org/10.1021/acsmedchemlett.6b00514, PMID: 28105267", "listPosition" : 167, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437047, "link" : "/api/reference/437047", "label" : "168. Stephenson, D.T., Coskran, T.M., Kelly, M.P., Kleiman, R.J., Morton, D., O’Neill, S.M., Schmidt, C.J., Menniti, F.S., The distribution of phosphodiesterase 2A in the rat brain (2012) Neuroscience, 226, pp. 145-155. , http://dx.doi.org/10.1016/j.neuroscience.2012.09.011, PMID: 23000621", "listPosition" : 168, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437046, "link" : "/api/reference/437046", "label" : "169. Stephenson, D.T., Coskran, T.M., Wilhelms, M.B., Adamowicz, W.O., O’Donnell, M.M., Muravnick, K.B., Menniti, F.S., Morton, D., Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species (2009) J. Histochem. Cytochem, 57 (10), pp. 933-949. , http://dx.doi.org/10.1369/jhc.2009.953471, PMID: 19506089", "listPosition" : 169, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437045, "link" : "/api/reference/437045", "label" : "170. Dyck, B., Branstetter, B., Gharbaoui, T., Hudson, A.R., Breitenbucher, J.G., Gomez, L., Botrous, I., Tabatabaei, A., Discovery of selective phosphodiesterase 1 inhibitors with memory enhancing properties (2017) J. Med. Chem, 60 (8), pp. 3472-3483. , http://dx.doi.org/10.1021/acs.jmedchem.7b00302, PMID: 28406621", "listPosition" : 170, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437044, "link" : "/api/reference/437044", "label" : "171. Clinical trial study found in clinical trials for ITI-214: NCT03489772, , https://clinicaltrials.gov/ct2/show/NCT03489772, (Accessed October 30, 2019)", "listPosition" : 171, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437043, "link" : "/api/reference/437043", "label" : "172. Clinical trial study found in clinical trials for ITI-214: NCT01900522, , https://clinicaltrials.gov/ct2/show/NCT01900522, (Accessed October 30, 2019)", "listPosition" : 172, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437042, "link" : "/api/reference/437042", "label" : "173. Li, P., Zheng, H., Zhao, J., Zhang, L., Yao, W., Zhu, H., Beard, J.D., Wennogle, L.P., Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases (2016) J. Med. Chem, 59 (3), pp. 1149-1164. , http://dx.doi.org/10.1021/acs.jmedchem.5b01751, PMID: 26789933", "listPosition" : 173, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 437041, "link" : "/api/reference/437041", "label" : "174. Polgár, M., Vereczkey, L., Nyáry, I., Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion (1985) J. Pharm. Biomed. Anal, 3 (2), pp. 131-139. , http://dx.doi.org/10.1016/0731-7085(85)80016-9, PMID: 16867695", "listPosition" : 174, "published" : false, "snippet" : true } ], "hasCitationDuplums" : false, "userChangeableUntil" : "2021-01-27T20:01:13.490+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 5, "ownerInstituteCount" : 42, "directInstituteCount" : 0, "authorCount" : 2, "contributorCount" : 0, "hasQualityFactor" : true, "link" : "/api/publication/31644451", "label" : "Al-Nema M.Y. et al. Phosphodiesterase as a target for cognition enhancement in schizophrenia. (2020) CURRENT TOPICS IN MEDICINAL CHEMISTRY 1568-0266 1873-4294 20 26 2404-2421", "template" : "